Cargando…
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma
PURPOSE: Adequately prioritizing the numerous therapies and biomarkers available in late-stage testing for patients with glioblastoma (GBM) requires an efficient clinical testing platform. We developed and implemented INSIGhT (Individualized Screening Trial of Innovative Glioblastoma Therapy) as a n...
Autores principales: | Alexander, Brian M., Trippa, Lorenzo, Gaffey, Sarah, Arrillaga-Romany, Isabel C., Lee, Eudocia Q., Rinne, Mikael L., Ahluwalia, Manmeet S., Colman, Howard, Fell, Geoffrey, Galanis, Evanthia, de Groot, John, Drappatz, Jan, Lassman, Andrew B., Meredith, David M., Nabors, L. Burt, Santagata, Sandro, Schiff, David, Welch, Mary R., Ligon, Keith L., Wen, Patrick Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448806/ https://www.ncbi.nlm.nih.gov/pubmed/32914038 http://dx.doi.org/10.1200/PO.18.00071 |
Ejemplares similares
-
Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019) -
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial
por: Griguer, Corinne E, et al.
Publicado: (2021) -
What is a glioblastoma?
por: Lassman, Andrew B, et al.
Publicado: (2023) -
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
por: Singh, Kirit, et al.
Publicado: (2022) -
CLRM-01. MACHINE LEARNING TO UNCOVER SIGNATURES OF VULNERABILITY IN GLIOBLASTOMA UMBRELLA SIGNATURE TRIAL (GUST)
por: Peng, Sen, et al.
Publicado: (2021)